CD274 and melanoma: Based on these data, a randomized Phase 2 study (NIBIT-ML1) was initiated, where NSCLC and melanoma patients resistant to PD1/PD-L1 therapies will receive either a triplet of nivolumab/ipilimumab/guadecitabine or the doublet of nivolumab/ipilimumab (NCT04250246).